Pegcetacoplan治疗后的视觉功能获益:3期OAKS试验的微视野分析
该研究为3期随机对照试验OAKS的事后分析,纳入605例继发于年龄相关性黄斑变性(AMD)的地图样萎缩(GA)患眼,评估玻璃体腔注射Pegcetacoplan每月(PM)或隔月(PEOM)与假注射相比对微视野终点的影响。结果显示,与假注射相比,Pegcetacoplan治疗延缓了中心4个和16个绝对暗点的出现时间,并减少了地图样萎缩交界区绝对暗点数量及视网膜敏感度下降。
要点
- 与假注射相比,Pegcetacoplan每月及隔月治疗均延缓了中心4个绝对暗点的出现时间(PM:HR 0.66,P=0.0282;PEOM:HR 0.64,P=0.0164)。
- 与假注射相比,Pegcetacoplan每月及隔月治疗均延缓了中心16个绝对暗点的出现时间(PM:HR 0.57,P=0.0361;PEOM:HR 0.52,P=0.0084)。
- 隔月治疗组交界区绝对暗点数量较假注射组减少(差值-1.14个,P=0.0140),平均视网膜敏感度下降减少(差值0.71 dB,P=0.0202)。
核心结论
- 微视野检查显示,Pegcetacoplan治疗可降低AMD所致地图样萎缩眼中心黄斑及交界区视觉功能丧失的速率。
研究设计与样本
- 3期随机对照试验OAKS研究的事后分析,纳入605例继发于AMD的地图样萎缩患眼,比较Pegcetacoplan每月(PM)或隔月(PEOM)与假注射,微视野终点在基线及每6个月评估至24个月,采用10-2网格68点及4-2阈值策略。
主要发现
- 与假注射组相比,Pegcetacoplan每月组和隔月组中心4个绝对暗点出现时间均延迟(PM:HR 0.66,95%CI 0.46-0.96,P=0.0282;PEOM:HR 0.64,95%CI 0.44-0.92,P=0.0164)。
- 与假注射组相比,Pegcetacoplan每月组和隔月组中心16个绝对暗点出现时间均延迟(PM:HR 0.57,95%CI 0.33-0.96,P=0.0361;PEOM:HR 0.52,95%CI 0.32-0.85,P=0.0084)。
- 在24个月时,与假注射组相比,Pegcetacoplan每月组交界区绝对暗点数量差异为-0.68个(P=0.1444),隔月组差异为-1.14个(P=0.0140)。
- 在24个月时,与假注射组相比,Pegcetacoplan每月组平均视网膜敏感度下降差异为0.56 dB(P=0.0650),隔月组差异为0.71 dB(P=0.0202)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the impact of pegcetacoplan on its ability to slow the loss of visual function using microperimetry endpoints in eyes with geographic atrophy secondary to age-related macular degeneration (AMD). DESIGN: Post hoc analysis of phase 3 randomized controlled trial data. METHODS: Utilizing data from the OAKS study, which evaluated pegcetacoplan monthly (PM) or every other month (PEOM) vs sham for the treatment of GA secondary to AMD, microperimetry endpoints were assessed at baseline and every 6 months until 24 months, using a 10-2 grid composed of 68 points with a 4-2 threshold strategy. Main outcome measures included the time to development of absolute scotomas in the 4 and 16 central macular points. The number of absolute scotomatous points and mean retinal sensitivity (dB) within the junctional zone extending to 250 µm on either side of autofluorescence-determined GA border was analyzed for change from baseline. RESULTS: Among 605 patients with subfoveal or nonsubfoveal GA, treatment with pegcetacoplan delayed time to development of absolute scotomas of all 4 central macular points compared to sham at 24 months (PM: hazard ratio [HR]: 0.66 [34% risk reduction]; 95% confidence interval [CI]: 0.46, 0.96; P = .0282; PEOM: HR: 0.64 [36% risk reduction]; 95% CI: 0.44, 0.92; P = .0164). Similarly, PM and PEOM treatment delayed time to development of absolute scotomas of all 16 central points (PM: HR: 0.57 [43% risk reduction]; 95% CI: 0.33, 0.96; P = .0361; PEOM: HR: 0.52 [48% risk reduction]; 95% CI: 0.32, 0.85; P = .0084). Across the junctional zone of GA, pegcetacoplan-treated eyes developed fewer absolute scotomatous points (PM difference vs sham pooled: -0.68 points, P = .1444; PEOM difference vs sham pooled: -1.14 points, P = .0140) and experienced decreased loss of mean retinal sensitivity (PM difference vs sham pooled: 0.56 dB, P = .0650; PEOM difference vs sham pooled: 0.71 dB, P = .0202) compared with sham at 24 months. CONCLUSIONS: Microperimetry demonstrates a reduced rate of visual function loss in the central macula and junctional zone with pegcetacoplan treatment in GA due to AMD.
引用
- Chakravarthy U, Schwartz R, Guymer RH, et al. Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial. Am J Ophthalmol. 2025. PMID: 39954920. doi:10.1016/j.ajo.2025.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。